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Abstract
Introduction. The aim of this study was to explore the effect of maternal
fluorinated steroid therapy on fetuses affected by second-degree immune-
mediated congenital atrioventricular block. Material and methods. Studies
reporting the outcome of fetuses with second-degree immune-mediated
congenital atrioventricular block diagnosed on prenatal ultrasound and
treated with fluorinated steroids compared with those not treated were
included. The primary outcome was the overall progression of congenital
atrioventricular block to either continuous or intermittent third-degree
congenital atrioventricular block at birth. Meta-analyses of proportions using
random effect model and meta-analyses using individual data random-effect
logistic regression were used. Results. Five studies (71 fetuses) were included.
The progression rate to congenital atrioventricular block at birth in fetuses
treated with steroids was 52% (95% confidence interval 23–79) and in fetuses
not receiving steroid therapy 73% (95% confidence interval 39–94). The
overall rate of regression to either first-degree, intermittent first-/second-
degree or sinus rhythm in fetuses treated with steroids was 25% (95%
confidence interval 12–41) compared with 23% (95% confidence interval 8–
44) in those not treated. Stable (constant) second-degree congenital
atrioventricular block at birth was present in 11% (95% confidence interval
2–27) of cases in the treated group and in none of the newborns in the
untreated group, whereas complete regression to sinus rhythm occurred in
21% (95% confidence interval 6–42) of fetuses receiving steroids vs. 9%
(95% confidence interval 0–41) of those untreated. Conclusions. There is still
limited evidence as to the benefit of administered fluorinated steroids in
terms of affecting outcome of fetuses with second-degree immune-mediated
congenital atrioventricular block.
Abbreviations: AV, atrio-ventricular; AVB, congenital atrioventricular block; CI,
confidence interval; NOS, Newcastle-Ottawa Scale.
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Introduction
Congenital atrioventricular block (AVB) encompasses a
wide spectrum of conditions characterized by the inter-
ruption of the conduction of electrical impulses from the
atria to the ventricles (1,2). First-degree AVB is character-
ized by a prolonged atrioventricular (AV) interval,
whereas in second-degree ABV, some beats are conducted
and others are blocked. In third-degree AVB, there is
complete interruption of AV conduction so that atria and
ventricles beat independently (1,2). AVB can occur in
fetuses with congenital heart disease; however, when iso-
lated it is commonly associated with maternal autoanti-
bodies, especially SSA/Ro and SSB/La (3,4). Although the
pathophysiology of immune-mediated AVB has not been
fully elucidated, transplacental passage of maternal IgG
antibodies with subsequent inflammation and fibrous
replacement of the conduction system is the most likely
explanation (4).
Early gestational age at diagnosis, low ventricular rate
and the presence of fetal hydrops have been reported to
be the major determinants of perinatal outcome in fetuses
affected by immune-mediated AVB (1,2). Despite this,
optimal management once AVB has been detected in
utero has yet to be established (5).
Whereas third-degree AVB is usually irreversible once
established, several reports suggest that fluorinated ster-
oids such as betamethasone and dexamethasone may
prevent in utero progression of immune-mediated sec-
ond-degree AVB and may improve the short- and long-
term outcome in these children (6,7). However, there is
still a paucity of data on the actual role of antenatal ster-
oids in the management of fetuses affected by second-
degree AVB. Series published to date differ in conclusions
and have small sample sizes (8–12).
The primary aim of this systematic review is to ascer-
tain whether maternal steroid therapy can prevent the
progression of second-degree immune-mediated AVB in
utero. Secondary aims are to explore the association
between steroid therapy and regression of AVB, pace-
maker implantation after birth, and fetal and neonatal
mortality.
Material and methods
This review was performed according to a protocol
designed a priori and recommended for systematic review
(13). MEDLINE, Embase and ClinicalTrials.gov databases
were searched electronically on 30 July 2017 utilizing
combinations of the relevant medical subject heading
(MeSH) terms, key words and word variants for “fetal
heart block,” “autoimmune disease,” “echocardiography,”
“corticosteroids” and “outcome.” Reference lists of
relevant articles and reviews were hand-searched for addi-
tional reports. Before data extraction, the review was reg-
istered with the PROSPERO International Prospective
Register of Systematic Reviews (registration no.:
CRD42016045713) following the PRISMA guidelines for
protocols (PRISMA-P) (14).
Only studies reporting the outcome of fetuses affected
by second-degree immune-mediated AVB who were trea-
ted with fluorinated steroids compared with those who
were not treated were considered eligible for inclusion
(13). Cases with non-immune AVB, those for whom
maternal antibody status could not be ascertained and
those associated with major congenital heart disease were
excluded. Therapy with steroids included the use of any
type of fluorinated corticosteroid.
Two authors (A.C., F.D.A.) reviewed all abstracts inde-
pendently. Agreement regarding potential relevance was
reached by consensus with a third reviewer (V.B.); full
text copies of those articles were obtained and the first
two reviewers independently extracted relevant data
regarding study characteristics and pregnancy outcome.
Inconsistencies were discussed and consensus was reached
or the dispute was resolved by discussion with a third
author. If more than one study was published for the
same cohort with identical endpoints, the report contain-
ing the most comprehensive information on the popula-
tion was included to avoid overlapping populations. The
authors of those articles in which information was not
reported but the methodology was such that this
information would have been recorded initially, were
contacted.
Quality assessment of the included studies was per-
formed using the Newcastle-Ottawa Scale (NOS). Accord-
ing to NOS, each study is judged on three broad
perspectives: the selection of the study groups, the com-
parability of the groups and the ascertainment outcome
of interest. Assessment of the selection of a study includes
the evaluation of the representativeness of the exposed
cohort, selection of the non-exposed cohort, ascertain-
ment of exposure and the demonstration that outcome of
interest was not present at start of study. Assessment of
the comparability of the study includes the evaluation
of the comparability of cohorts on the basis of the design
or analysis. Finally, the ascertainment of the outcome of
Key Message
There is still limited evidence as to the benefit of
administered fluorinated steroids in terms of affecting
outcome of fetuses with second-degree immune-
mediated congenital atrioventricular block.
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interest includes the evaluation of the type of the assess-
ment of the outcome of interest and the length and ade-
quacy of follow up. According to NOS, a study can be
awarded a maximum of one star for each numbered item
within the Selection and Outcome categories. A maxi-
mum of two stars can be given for Comparability (15).
The primary outcome was the overall progression of
AVB to either intermittent (second/third) or continuous
III degree AVB at birth (overall progression).
The secondary outcomes were:
• Regression to either first-degree, intermittent first-/sec-
ond-degree AVB or sinus rhythm (overall regression)
• Regression to first-degree AVB
• Regression to intermittent first-/second-degree AVB
• Regression to sinus rhythm
• Persistence of second-degree AVB
• Fetal death
• Neonatal death
• Pacemaker insertion
First-degree immune-mediated AVB was diagnosed at
M-mode or pulsed wave Doppler ultrasound when the
AV conduction time was prolonged. Prenatal diagnosis of
second-degree AVB was done in the presence of a pro-
gressive lengthening of AV conduction, until an isolated
impulse was blocked (Mobitz I) or, in the case of a sud-
den block of an isolated impulse, without prior lengthen-
ing of the AV conduction time (Mobitz II). Finally,
third-degree AVB was diagnosed when there was no AV
conduction (2), with the atria and ventricles beating inde-
pendently (1,2).
Second-degree immune-mediated AVB was defined
as continuous when the postnatal electrocardiographic
tracing showed the presence of permanent and con-
stant second-degree AVB, and intermittent when there
was an alternation between second- and third-degree
AVB (1,2).
We aimed to ascertain the occurrence of each of the
explored outcomes either at the first electrocardiographic
assessment after birth or at follow up, which we defined
as the last assessment according to the duration of each
study (preferably at 1 year).
To quantify the incidence of the outcome explored,
meta-analyses of proportions using random effect model
were used to combine data. Funnel plots displaying the
outcome rate from individual studies vs. their precision
(1/standard error) were carried out with an exploratory
aim. Tests for funnel plot asymmetry were not used when
the total number of publications included for each out-
come was less than 10; in this case, the power of the tests
is too low to distinguish chance from real asymmetry
(16–19). Between-study heterogeneity was explored using
the I2 statistic, which represents the percentage of
between-study variation that is due to heterogeneity
rather than chance (19).
Furthermore, we evaluated separately the risk of overall
regression, overall progression, fetal and neonatal death,
and postnatal pacemaker implantation in fetuses that
were treated compared with those not treated prenatally
with steroids. We included observational cohort studies
in which: (i) comparisons reported zero events in one
groups; (ii) comparisons reported zero events in both
groups; (iii) exposed and unexposed group sizes were
unbalanced. In such a case, many of the most commonly
used meta-analytical methods – including those using risk
difference (which can be used to handle total zero event
studies) – may produce biased estimates when events are
rare (20–22). When many studies are also substantially
imbalanced, the best performing methods are the Mantel–
Haenszel odds ratio without zero-cell continuity correc-
tions, logistic regression and an exact method. Mantel–
Haenszel odds ratios cannot be computed in studies
reporting zero events in both groups, the exclusion of
which may, however, cause a relevant loss of information
and the potential inflation of the magnitude of the
pooled exposure effect. Therefore, to keep all studies in
the analyses, we performed all meta-analyses using indi-
vidual data random-effect logistic regression, with single
study as the cluster unit (20–22). The pooled datasets
with individual data were reconstructed using published
2 9 2 tables. When one of the overall pooled arms showed
no events, we used exact logistic regression (20–22).
Finally, a Wald test was performed to explore the power of
the test for each given sample size.
All analyses were performed using StatsDirect Ltd.
STATSDIRECT statistical software (England: StatsDirect
Ltd. 2013) and STATA version 13.1 (2013; StataCorp,
College Station, TX, USA).
Results
Of the 426 articles identified, 46 were assessed with
respect to their eligibility for inclusion (Table S1) and
five were included in the systematic review (Table 1, Fig-
ure 1). All pregnancies included were positive for SSA/Ro
and SSB/La antibodies. Maternal therapy other than fluo-
rinated steroids was not described in detail in the major-
ity of the included studies (Table 1). The route of steroid
administration was enteral in all included studies.
No randomized controlled trial on steroid therapy in
fetuses affected compared with those not affected by sec-
ond-degree immune-mediated AVB was found in the
medical databases explored, thus only non-randomized
studies were included. These five studies included 71
fetuses with a prenatal diagnosis of second-degree
immune-mediated AVB.
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The included studies differed in their inclusion criteria
and not all the included cases had a clear prospective
diagnosis of second-degree immune-mediated AVB dur-
ing pregnancy, as some of the cases presented as brady-
cardia in women with unknown immune status. The
study by Doti et al. (8) included cases followed up longi-
tudinally during pregnancy, but the other studies did not
specify whether the diagnosis of second-degree immune-
mediated AVB was carried out prospectively or retrospec-
tively (i.e. fetuses presenting with bradycardia in women
with unknown immune status). Although the studies by
Friedman et al. (12) and Izmirly et al. (10) included cases
from the same population, they were both included in
the present systematic review because they examined dif-
ferent outcome measures. Dexamethasone was the fluori-
nated steroid used in the vast majority of included
Table 1. General characteristics of the included studies.
Author Year Country Study design Time interval Cases, n
Steroid
type Dose Follow-up Post natal assestment
Doti (8) 2016 Spain Retrospective 1997–2014 5 DEX NS NS 12-lead ECG
Levesque (9) 2015 France Retrospective 2000–2014 24 DEX NS 12.7 years EKG and/or
echocardiography
Izmirly (10) 2011 USA Retrospective From 2010 21 DEX NS NS NS
Eliasson (11) 2011 Europe/
Brazil
Retrospective 2000–2006 7 DEX, BET DEX, 4 mg/day
(2–12)
BET 4 mg/day
(3–5)
3.2 years NS
Friedman (12) 2009 United
States
Prospective 2000–2006 6 DEX 4 mg/day 2 years EKG and
echocardiography at
birth and at 1 year
BET, betamethasone; DEX, dexamethasone; EKG, electrocardiography, GA, gestational age; NS, not stated.
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Figure 1. Systematic review flowchart. [Color figure can be viewed at wileyonlinelibrary.com].
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studies at a preferred dose of 4–8 mg/day, although the
dose protocol and the gestational age at administration of
the drug were not reported in all the studies. The interval
between diagnosis and treatment was reported only in the
study by Doti et al. (8), in which dexamethasone was
started the same day as the diagnosis. Type and timing of
postnatal assessment was reported in only a few of the
included studies (Table 1). Unfortunately, heterogeneity
and lack of information on time at follow up did not
allow a comprehensive data synthesis to be performed
regarding the occurrence of the explored outcome at fol-
low up; thus we reported only the prevalence of each
observed outcome at birth.
Quality assessment of the included studies performed
using NOS for cohort studies is shown in Table 2. Most
of the included studies showed an overall good rate with
regard to the selection and comparability of the study
groups. The main weaknesses of these studies were their
retrospective designs, small sample size and the large
heterogeneity in drug protocols, gestational ages at ther-
apy and the duration of follow up.
Progression
Four studies (42 cases) explored the likelihood of overall
progression of the block, defined as a progression towards
either intermittent second/third or third-degree (com-
plete) AVB (7,8,10,11). The progression rate in fetuses
treated with steroids was 52% (95% CI 23–79), whereas
the rate in fetuses not receiving steroid therapy was 73%
(95% CI 39–94) at birth (Table 3, Figure 2). The large
majority of fetuses progressed to persistent third-degree
AVB, whereas only a small proportion of them progressed
to intermittent forms of AVB.
Regression
The overall rate of regression at birth from prenatal to
first-degree, intermittent first-/second-degree or sinus
rhythm in fetuses treated with steroids was 25% [95%
confidence interval (CI) 12–41] compared with 23%
(95% CI 8–44) in those not treated (Table 3). Regression
to first-degree AVB at birth occurred in 5% (95% CI 0-
15) of cases in the steroid group and 18% (95% CI 2–52)
in untreated fetuses. Stable (persistent) second-degree
AVB at birth occurred in 11% (95% CI 2–27) of the trea-
ted group and in none of the newborns in the untreated
group, mainly because of the higher proportion of
untreated fetuses progressing to third-degree AVB
(Table 2). Complete regression to sinus rhythm occurred
at birth in 21% (95% CI 6–42) of fetuses receiving ster-
oids vs. 9% (95% CI 0–41) of those untreated.
Fetal and neonatal death, and permanent
pacemaker implantation
Fetal death occurred in none of the cases in the treated
group; no information on the occurrence or either fetal
or neonatal death could be extrapolated from the
untreated group (Table 3).
Five studies including 58 fetuses explored the rate of
postnatal pacemaker insertion. A permanent pacemaker
was implanted postnatally in 25% (95% CI 9–46) of cases
treated with steroids and in 50% (95% CI 16–84) of
those receiving no treatment; it was mainly related to a
higher rate of progression to third-degree AVB observed
in the untreated group.
Assessment of the risk of each of the outcomes in the
present systematic review was problematic as only a small
proportion of the included studies reported a direct com-
parison between fetuses treated and those not treated
with steroids (Table S2). The very small number of
included cases led to a lack of statistical power which pre-
cluded a comprehensive assessment of the strength of
association between antenatal steroid therapy and each of
the outcomes observed. In our review, antenatal steroid
therapy was not associated with a statistically significant
reduced risk of regression, and it was not possible to
compute the odds ratios for the progression of AVB, sur-
vival and pacemaker insertion. In view of these limita-
tions, the figures for the odds ratios reported in this
systematic review should be interpreted with caution and
may not reflect the actual strength of association between
antenatal steroid therapy and the outcomes observed.
Discussion
The findings from this systematic review show that there
is still limited evidence on the role of fluorinated steroids
in affecting the natural history of second-degree immune-
mediated AVB in utero. Progression to continuous or
intermittent second/third-degree AVB occurred in 52% of
fetuses treated with maternal steroids and in 73% of those
Table 2. Quality assessment of the included studies according to
Newcastle-Ottawa Scale (NOS) a study can be awarded a maximum
of one star for each numbered item within the Selection and
Outcome categories. A maximum of two stars can be given for
Comparability.
Author Year Selection Comparability Outcome
Doti (8) 2016 ★ ★★ ★★
Levesque (9) 2015 ★ ★ ★★
Izmirly (10) 2011 ★★ ★ ★
Eliasson (11) 2011 ★★ ★ ★★
Friedman (12) 2009 ★★ ★★ ★★
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not treated. Persistent second-degree AVB was present at
birth in 11% of treated fetuses and in none of the
untreated. Postnatal pacing was required in 25% of trea-
ted vs. 50% of untreated fetuses. In view of the very small
number of included cases and the subsequent lack of sta-
tistical power, it was not possible to quantify objectively
the strength of association between fluorinated steroid
therapy and any of the observed outcomes.
This is the first meta-analysis assessing the role of ante-
natal steroid administration in fetuses affected by second-
degree immune-mediated AVB. The strengths of this
study are its robust methodology for identifying all possi-
ble studies for inclusion, assessing data quality and syn-
thesizing all suitable data. Another strength of this review
is the inclusion of cases treated only with corticosteroids
in order to reduce the bias associated with the presence
of other co-treatments.
The very small number of included studies, their retro-
spective non-randomized design, different periods of fol-
low up, lack of information on postnatal confirmation of
the arrhythmia, dissimilarity in the populations (due to
varied inclusion criteria) and a lack of fixed criteria for
when to treat represented the major limitations of this
meta-analysis. Assessment of the potential publication
bias was also problematic both because of the outcome
nature (rates with the left side limited to the value zero),
which limits the reliability of funnel plots, and because of
the scarce number of individual studies, which strongly
limits the reliability of formal tests. Many of the included
studies were non-controlled. The level of evidence for this
Table 3. Pooled proportions for the different outcomes observed in this systematic review.
Outcome
Fetuses treated Fetuses not treated
Studies Fetuses I2 Pooled % (95% CI) Studies Fetuses I2 Pooled % (95% CI)
Overall progression 47,8,10,11 17/31 65.3 51.53 (23.2–79.3) 18 8/11 – 72.73 (39.0–94.0)
Progression to second-/third-degree AVB 47,8,10,11 1/31 0 6.07 (0.6–16.6) 18 0/11 – 0 (0–28.5)
Progression to third-degree AVB 47,8,10,11 16/31 57 49.36 (23.9–75.0) 18 8/11 – 72.73 (39.0–94.0)
Overall regression 47–10 9/38 15.7 25.09 (12.0–41.1) 28,9 4/19 0 23.32 (7.9–43.8)
Regression to first-degree AVB 47–9,11 1/31 0 4.80 (0.3–14.6) 18 2/11 – 18.18 (2.3–51.8)
Partial regression (intermittent
first-/second-degree AVB)
47–9,11 0/31 0 0 (0–11.1) 18 0/11 – 0 (0–28.5)
Regression to sinus rhythm 47–9,11 6/31 42.2 20.55 (5.7–41.6) 18 1/11 – 9.10 (0.2–41.3)
Stable rhythm 47–10 4/38 40 11.00 (1.8–26.7) 28,9 0/19 0 0 (0–13.5)
Fetal death 27,10,11 0/16 0 0 (0–17.8) – – – –
Neonatal death 27,10,11 0/16 0 0 (0–17.8) – – – –
Pacemaker insertion 27,9 4/18 0 24.80 (8.5–46.1) 1 8/4 4 50.00 (15.7–84.3)
AVB, congenital atrioventricular block.
Progression (Fetuses treated) Progression (Fetuses not treated)
At birth and at follow up
Combined
Friedman
Eliasson
Lavesque
Doti
Combined
Eliasson
Lavesque
0.52 (0.23. 0.79)
0.17 (4.2E-3. 0.64)
0.29 (0.04. 0.71)
0.77 (0.46. 0.95)
0.80 (0.28. 0.99)
0.67 (0.45. 0.85)
0.63 (0.24. 0.91)
0.73 (0.39. 0.94)
Proportion (95% confidence interval) Proportion (95% confidence interval)
0.00 0.25 0.50 0.75 1.00 0.20 0.45 0.70 0.95
Figure 2. Pooled proportions for the rate of progression of second-degree congenital atrioventricular block at birth and at follow up in fetuses
treated and in those not treated with steroids.
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type of study is very low. Furthermore, we could not
stratify the analysis according to gestational age at diag-
nosis and treatment, type of AV conduction block (Mob-
itz I vs. II), antibody levels, time at follow up and the
drug protocol adopted, as this information was reported
only in a small number of included cases. The interval
between prenatal diagnosis and treatment is another rele-
vant issue, as it is plausible that steroid therapy may be
more effective if started immediately after diagnosis. In
addition, the large majority of the included studies did
not differentiate between immune and non-immune
AVB; this is fundamental, because steroid therapy is likely
to be beneficial only in immune-mediated AVB.
The occurrence of co-treatments is another relevant
issue. Cases receiving multiple forms of treatment for fetal
AVB were excluded from the present systematic review.
However, it is entirely possible that some fetuses identified
by us as having been treated only with steroids may have
received additional co-treatments not specified in the origi-
nal report, thus potentially biasing the results.
Despite these limitations, the present review represents
the most comprehensive published estimate of the effect
of maternal steroid therapy on second-degree immune-
mediated AVB.
Prenatal diagnosis of fetal arrhythmias is challenging
and requires an indirect assessment of the heart rhythm
using M-mode or pulsed-wave Doppler ultrasound (1,2).
Furthermore, differential diagnosis of fetal arrhythmias is
not always feasible in utero and second-degree AVB may
be sometimes difficult to differentiate from atrial bigemi-
nism with blocked premature atrial contractions (PACs)
and from both third-degree AVB and isorhythmic dissoci-
ation (1,2).
Antenatal steroid treatment of fetuses with a second-
degree AVB has been suggested to improve myocardial per-
formance and to prevent progression to third-degree AVB,
which is associated with a high burden of perinatal mortal-
ity and morbidity, permanent pacemaker implantation and
late onset cardiomyopathy. The rationale for steroid
administration in this setting relates to its potential anti-
inflammatory and immunosuppressive effects and the pos-
sibility that it may inhibit the development of conduction
system disease and even reverse cardiac failure.
In the present systematic review, estimation of the
pooled odds ratios for the different outcomes explored
was limited by the small number of included studies, pre-
venting us from reaching an adequate statistical power.
Despite this, it is the collective authors’ opinion that the
use of corticosteroids once second-degree AVB is diag-
nosed should not be discouraged until more robust evi-
dence is available.
Large prospective and adequately powered randomized
trials are needed to elucidate the role of maternal
fluorinated steroid therapy in modifying the natural his-
tory of second-degree immune-mediated AVB in utero.
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